<unk>  is a kinase inhibitor that is FDA approved for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include nausea, rash, headache, fatigue, pruritus, vomiting, diarrhea, cough, constipation, arthralgia, nasopharyngitis, pyrexia, and night sweats.
Nilotinib
Crizotinib
Afatinib
Erlotinib
Axitinib
Gefitinib
Neratinib
Erdafitinib